PT2428252E - Neutralização de atividade de blocos de invasão cd95 de células de glioblastoma in vivo - Google Patents

Neutralização de atividade de blocos de invasão cd95 de células de glioblastoma in vivo Download PDF

Info

Publication number
PT2428252E
PT2428252E PT11190918T PT11190918T PT2428252E PT 2428252 E PT2428252 E PT 2428252E PT 11190918 T PT11190918 T PT 11190918T PT 11190918 T PT11190918 T PT 11190918T PT 2428252 E PT2428252 E PT 2428252E
Authority
PT
Portugal
Prior art keywords
neutralization
vivo
glioblastoma cells
activity blocks
blocks invasion
Prior art date
Application number
PT11190918T
Other languages
English (en)
Portuguese (pt)
Inventor
Ana Martin-Villalba
Susanne Kleber
Benedikt Wiestler
Peter G Krammer
Christel Herold-Mende
Original Assignee
Universitätsklinikum Heidelberg
Deutsches Krebsforsch
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Universitätsklinikum Heidelberg, Deutsches Krebsforsch filed Critical Universitätsklinikum Heidelberg
Publication of PT2428252E publication Critical patent/PT2428252E/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2875—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF/TNF superfamily, e.g. CD70, CD95L, CD153, CD154
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70575—NGF/TNF-superfamily, e.g. CD70, CD95L, CD153, CD154
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70578—NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/566—Immunoassay; Biospecific binding assay; Materials therefor using specific carrier or receptor proteins as ligand binding reagents where possible specific carrier or receptor proteins are classified with their target compounds
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6863—Cytokines, i.e. immune system proteins modifying a biological response such as cell growth proliferation or differentiation, e.g. TNF, CNF, GM-CSF, lymphotoxin, MIF or their receptors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/70578—NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30 CD40 or CD95
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/04—Screening involving studying the effect of compounds C directly on molecule A (e.g. C are potential ligands for a receptor A, or potential substrates for an enzyme A)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/10—Screening for compounds of potential therapeutic value involving cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2510/00—Detection of programmed cell death, i.e. apoptosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Cell Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Pathology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hospice & Palliative Care (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
PT11190918T 2006-12-28 2007-12-28 Neutralização de atividade de blocos de invasão cd95 de células de glioblastoma in vivo PT2428252E (pt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US87736706P 2006-12-28 2006-12-28

Publications (1)

Publication Number Publication Date
PT2428252E true PT2428252E (pt) 2014-12-11

Family

ID=39400900

Family Applications (2)

Application Number Title Priority Date Filing Date
PT11190918T PT2428252E (pt) 2006-12-28 2007-12-28 Neutralização de atividade de blocos de invasão cd95 de células de glioblastoma in vivo
PT78571536T PT2101877E (pt) 2006-12-28 2007-12-28 Neutralização de atividade de blocos de invasão cd95 de células de glioblastoma in vivo

Family Applications After (1)

Application Number Title Priority Date Filing Date
PT78571536T PT2101877E (pt) 2006-12-28 2007-12-28 Neutralização de atividade de blocos de invasão cd95 de células de glioblastoma in vivo

Country Status (12)

Country Link
US (2) US9309320B2 (enExample)
EP (2) EP2428252B1 (enExample)
JP (2) JP5558828B2 (enExample)
AU (1) AU2007341631B9 (enExample)
CA (1) CA2673868C (enExample)
CY (1) CY1116006T1 (enExample)
DK (2) DK2101877T3 (enExample)
ES (2) ES2523992T3 (enExample)
PL (2) PL2428252T3 (enExample)
PT (2) PT2428252E (enExample)
SI (1) SI2428252T1 (enExample)
WO (1) WO2008080623A2 (enExample)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2963124C (en) 2007-07-10 2019-10-15 Apogenix Ag Tnf superfamily collectin fusion proteins
EP2318441A2 (en) * 2008-07-14 2011-05-11 Deutsches Krebsforschungszentrum, Stiftung des öffentlichen Rechts Use of cd95 inhibitors for the treatment of inflammatory disorders
US8664366B2 (en) 2009-01-09 2014-03-04 Apogenix Gmbh Fusion proteins forming trimers
EP2456468A1 (en) * 2009-07-21 2012-05-30 Queen Mary and Westfield College Fas (apo-1, cd95) targeted platforms for intracellular drug delivery
EP2322927A1 (en) * 2009-11-16 2011-05-18 Deutsches Krebsforschungszentrum Compounds inhibiting CD95 signaling for the treatment of pancreatic cancer
HK1207095A1 (en) * 2012-07-18 2016-01-22 阿珀吉尼科斯股份公司 Composition comprising a mixture of cd95-fc isoforms
EP2894472A4 (en) * 2012-09-05 2016-03-30 Jsr Corp METHOD OF SCREENING MATERIAL FOR EPITHELIAL CONSERVATION OF CELLS
BR112015027249A2 (pt) * 2013-04-29 2017-09-26 Apogenix Gmbh método de diagnóstico de câncer
US20160115237A1 (en) 2013-05-24 2016-04-28 The University Of British Columbia Cell senescence markers as diagnostic and therapeutic targets
EP3094744A1 (en) * 2014-01-15 2016-11-23 Apogenix AG Method of predicting the responsiveness of a cancer disease to treatment on the basis of dna methylation
EP3137909B1 (en) * 2014-04-29 2018-06-06 Apogenix AG Diagnostic anti-cd95l antibody
MA45488A (fr) 2015-10-22 2018-08-29 Juno Therapeutics Gmbh Procédés, kits et appareil de culture de cellules
AU2019403393A1 (en) * 2018-12-20 2021-08-05 The University Of Chicago Methods and compositions related to therapeutic peptides for cancer therapy

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5891434A (en) 1991-06-17 1999-04-06 Centocor, Inc. Monoclonal antibodies to the APO-1 antigen
CA2109398A1 (en) 1992-10-30 1994-05-01 Alejandro A. Aruffo Extracellular matrix receptor ligands that modulate leukocyte function
JPH08127594A (ja) 1993-11-10 1996-05-21 Mochida Pharmaceut Co Ltd Ｆａｓ抗原に結合する新規蛋白質およびそれをコードするＤＮＡ
DE4447484C2 (de) 1994-04-08 1997-07-17 Deutsches Krebsforsch Mittel zur Hemmung von Apoptose
US6060238A (en) * 1995-02-13 2000-05-09 The Regents Of The University Of Michigan Method and composition for regulating apoptosis
DE69636170T2 (de) 1995-03-20 2006-11-02 Okumura, Ko Monoklonaler antikörper, der spezifisch mit dem fas-liganden reagiert, und verfahren zu seiner herstellung
JP3925663B2 (ja) 1995-06-30 2007-06-06 持田製薬株式会社 抗Ｆａｓリガンド抗体および該抗体を用いた測定法
JPH09124509A (ja) 1995-10-27 1997-05-13 Sumitomo Electric Ind Ltd 肝炎治療剤
ATE299936T1 (de) 1996-05-02 2005-08-15 Mochida Pharm Co Ltd Fas antigen-derivate
EP1642908A2 (en) 1996-09-02 2006-04-05 Okumura, Ko Apoptosis-induced site from fas ligand
ATE393222T1 (de) 1997-09-18 2008-05-15 Genentech Inc Dcr3 polypeptid, ein tnfr homolog
CA2324517A1 (en) 1998-03-30 1999-10-07 Eli Lilly And Company Therapeutic applications of mature flint (mflint) polypeptides or opg3, a member of the tnf receptor superfamily
US6348573B1 (en) * 1998-04-27 2002-02-19 The Regents Of The University Of Michigan Compositions and methods for identifying apoptosis signaling pathway inhibitors and activators
US6846637B1 (en) 1998-06-18 2005-01-25 Imed Ab Fas peptides and antibodies for modulating apoptosis
US20030170244A1 (en) * 2001-12-21 2003-09-11 Pluenneke John D. Inhibition of Fas signaling
WO2003088975A1 (en) * 2002-04-17 2003-10-30 The Burnham Institute Inhibition of fatty acid synthase by beta-lactones and other compounds for inhibition of cellular proliferation
EP1447093A1 (en) 2003-02-14 2004-08-18 Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts Inhibition of the CD95 ligand/receptor system for the treatment of neurological disorders and injuries
JP2007533595A (ja) * 2003-03-26 2007-11-22 アポゲニクス ゲゼルシャフト ミット ベシュレンクテル ハフツング ウィルス感染の治療
US7445794B1 (en) * 2004-04-29 2008-11-04 The Regents Of The University Of Colorado Methods for treating human proliferative diseases, with a combination of fatty acid metabolism inhibitors and glycolytic inhibitors

Also Published As

Publication number Publication date
SI2428252T1 (sl) 2015-01-30
WO2008080623A3 (en) 2008-09-12
PT2101877E (pt) 2013-07-22
US9309320B2 (en) 2016-04-12
JP5558828B2 (ja) 2014-07-23
WO2008080623A2 (en) 2008-07-10
CY1116006T1 (el) 2017-01-25
JP2010514722A (ja) 2010-05-06
EP2101877B1 (en) 2013-06-19
AU2007341631B2 (en) 2012-08-30
US9850308B2 (en) 2017-12-26
US20160115236A1 (en) 2016-04-28
ES2523992T3 (es) 2014-12-03
DK2101877T3 (da) 2013-09-23
JP5893078B2 (ja) 2016-03-23
AU2007341631B9 (en) 2012-10-04
CA2673868C (en) 2016-03-22
JP2014167024A (ja) 2014-09-11
PL2101877T3 (pl) 2013-11-29
AU2007341631A1 (en) 2008-07-10
ES2420582T3 (es) 2013-08-26
EP2428252B1 (en) 2014-11-05
EP2101877A2 (en) 2009-09-23
US20100322922A1 (en) 2010-12-23
DK2428252T3 (en) 2015-02-16
CA2673868A1 (en) 2008-07-10
PL2428252T3 (pl) 2015-04-30
EP2428252A1 (en) 2012-03-14

Similar Documents

Publication Publication Date Title
PL2428252T3 (pl) Neutralizacja aktywności cd95 blokuje inwazję komórek glejaka in vivo
EP1851814A4 (en) SECONDARY BATTERY WITH IMPROVED LITHIUM MOBILITY AND CELL CAPACITY
GB2432723B (en) Electrochemical cell and method of manufacture
EP1946393A4 (en) BATTERY CELL DESIGN AND METHOD FOR THEIR CONSTRUCTION
IL208518A0 (en) Modified hyaluronidases and uses in treating hyaluronan-associated diseases and conditions
GB0524075D0 (en) Electrochemical cell and method of manufacture
IL189079A0 (en) Method of encapsulating therapeutic substances in cells
EP2111252A4 (en) MANAGEMENT OF PAIN BY ELECTROCHEMICAL PATHWAY
EP2036220A4 (en) CUMULATIVE LIST OF NEIGHBORING CELLS
IL207293A (en) Control of the living body of enzymes that break down an activatable matrix
GB0823074D0 (en) Design and method of assembly of cdi cells
PL2501693T3 (pl) Azaheterocykliczne akryloamidy i ich zastosowanie jako środków bakteriobójczych
EP2028264A4 (en) CELL INCUBATOR
EP2069477A4 (en) CHEMICAL REPULSION OF CELLS
GB0911331D0 (en) Characterising properties or behaviour of biological cells
GB2451030B (en) Improvements in or relating to battery packs
IL196480A0 (en) Improvement of arginase levels/activity
EP2185720A4 (en) BIOLOGICAL CODING OF A LARGE NUMBER OF CELLS
EP2023925A4 (en) CDKI PATH HEMMER AS SELECTIVE TEMPORARY GROWTH INHIBITORS
GB0901085D0 (en) Electrode and electrochemical sensor
SI2101877T1 (sl) Nevtralizacija aktivnosti CD95 za blokiranje invazije celic glioblastoma in vivo
EP1993953A4 (en) ELECTROCHEMICAL CELL WITH ION FLUORIDE
GB0609926D0 (en) Electrochemical cell
GB0604653D0 (en) Granularity analysis in cellular phenotypes
EP2130915A4 (en) CELL THAT CAN EXPRESS A LARGE QUANTITY OF LACRITIN